Interní Med. 2009; 11(4): 155-158

Significance of combinations of oral antidiabetics in type 2 diabetes treatment

doc. MUDr. Alena ©mahelová Ph.D
Klinika gerontologická a metabolická, FN Hradec Králové

Current options of type 2 diabetes pharmacotherapy are broad. Recent knowledge has had a major impact on the therapeutic regimen

and procedure and has proved that glycaemic compensation cannot be obtained without oral antidiabetics. Given the fact that oral

antidiabetics gradually lose efficacy as monotherapy, timely combinations of various types of antidiabetics at lower doses are required.

Other, almost invariably present disorders (arterial hypertension, dyslipidaemia, coagulation disorders) require complex pharmacological



treatment: In a number of patients, it is possible to use combinations of oral antidiabetics, which combine the effects of metphormin

and sulphonylurea or thiazolidindiones, increase patient compliance and thus treatment success.

Keywords: type 2 diabetes mellitus, metabolic syndrome, oral antidiabetics, fixed combinations of oral antidiabetics.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©mahelová A. Significance of combinations of oral antidiabetics in type 2 diabetes treatment. Interní Med. 2009;11(4):155-158.
Download citation

References

  1. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412. Go to original source... Go to PubMed...
  2. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 2009; 32: 187-192. Go to original source... Go to PubMed...
  3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidindiones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31(1): 173-175. Go to original source... Go to PubMed...
  4. ©mahelová A. Metformin. In Trendy v diabetologii 12, ed. M. Haluzík, Praha Galén 2008.
  5. Danchin, Charpentier G, Ledru F, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: result from a nationwide French registry. Diab Met Res Rev. 2005; 21: 143-149. Go to original source... Go to PubMed...
  6. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002; 45(7): 1034-1037. Go to original source... Go to PubMed...
  7. Jennings PE, Saniabadi AR, Belch JJ. Efeects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism 1999, 41 (suppl. 1): 36-39. Go to original source... Go to PubMed...
  8. Katakami N, Katakami Y, Hayaishi-Okano R, et al. Metformin or gliclazide, rather than glibenclamid, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004; 47: 1906-1913. Go to original source... Go to PubMed...
  9. Johnsen SP, Monster TBM, Olsen ML, et al. Risk and short term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006; 13: 134-137. Go to original source... Go to PubMed...
  10. Dormandy JA, Charbonnel B, Eckland DJ, et al. the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
  11. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, NEJM, 2007; 356: 2457-2471. Go to original source... Go to PubMed...
  12. Haluzík M. Svačina ©. Gliptiny. In Trendy v diabetologii 12, Galén Praha, 2008.
  13. Ahrén B. GLP-1-Based Therapy of Type 2 Diabetes: GLP-1 Mimetics and DPP-IV Inhibitors. Curr Diab Rep. 2007; 7 (5): 340-347. Go to original source... Go to PubMed...
  14. Rosenstock J, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30(2): 217-223. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.